Yusof Basmullah, Kamal Iqmaliza, Lee Ka Man, Chai Siong Kiat, Zuo Xia Lin, Ravichandran Manickam, Ding Ke Xiang, Fuloria Neeraj Kumar, Tham Seng Kong
ALPS Medical Centre, ALPS Global Holding, Kuala Lumpur, Malaysia.
Celestialab Sdn Bhd, Kuala Lumpur, Malaysia.
SAGE Open Med Case Rep. 2024 Apr 29;12:2050313X241249622. doi: 10.1177/2050313X241249622. eCollection 2024.
Umbilical cord-derived mesenchymal stem cells for regenerative therapy are a promising treatment option for chronic illnesses. Umbilical cord-derived mesenchymal stem cells offer several advantages over other sources, which makes them an attractive option in tissue repair and regeneration. This clinical study describes a 1-year follow-up on the safety and tolerance of umbilical cord-derived mesenchymal stem cell therapy on nine patients in Malaysia. Patients were assessed for adverse effects, and liver function tests were carried out on both pre- and post-treatments. Umbilical cord-derived mesenchymal stem cells' effectiveness and safety were assessed by follow-up evaluations. All nine patients responded positively towards umbilical cord-derived mesenchymal stem cell therapy, without any adverse effects. After umbilical cord-derived mesenchymal stem cell therapy, a significant improvement was observed in liver functioning test outcomes, as haematological parameters and tumour markers were stable. The present study concludes that umbilical cord-derived mesenchymal stem cell therapy is well tolerated by Malaysian patients; however, further clinical screening must be done over a large number of patients population.
用于再生治疗的脐带间充质干细胞是治疗慢性疾病的一种有前景的选择。与其他来源相比，脐带间充质干细胞具有多个优势，这使其在组织修复和再生方面成为一个有吸引力的选择。这项临床研究描述了对马来西亚9名患者进行脐带间充质干细胞治疗的安全性和耐受性的1年随访情况。对患者进行了不良反应评估，并在治疗前后都进行了肝功能测试。通过随访评估来评估脐带间充质干细胞的有效性和安全性。所有9名患者对脐带间充质干细胞治疗均反应积极，没有任何不良反应。在脐带间充质干细胞治疗后，肝功能测试结果有显著改善，血液学参数和肿瘤标志物保持稳定。本研究得出结论，马来西亚患者对脐带间充质干细胞治疗耐受性良好；然而，必须对大量患者群体进行进一步的临床筛查。
